Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI - Louie, T J; Cannon, K; Byrne, B (Clin Infect Dis, 2012)
, et al.